Printer Friendly

AIT Laboratories Announces Name, Brand Identity for New Division.

INDIANAPOLIS, May 18 /PRNewswire/ -- AIT Laboratories, which specializes in pain management, forensics, and clinical testing, is announcing that its newly created pharmaceutical testing division will be known as AIT Bioscience, LLC. Recently, AIT Laboratories announced that the division will be located at its Indianapolis, Ind. headquarters.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090518/DE18644LOGO )

"AIT Bioscience will operate under the same quality principles that I founded AIT Laboratories on 19 years ago," said AIT Laboratories President and CEO Michael A. Evans, Ph.D. "We have some of the industry's most veteran scientists leading the new division, including Ronald Shoup, Ph.D., who brings more than 30 years of leadership, entrepreneurship and scientific expertise to AIT Bioscience." Prior to joining AIT, Dr. Shoup was chief scientific officer of Bioanalytical Systems, Inc. in West Lafayette, Ind.

"Bioanalytical testing is closely aligned with what AIT Laboratories already does in terms of processes and equipment. AIT Bioscience wants to take those resources and apply them to the pharmaceutical industry in ways other CROs only wish they could," Shoup explained. "Our talent and lack of legacy systems allow us to build an organization from the ground up that caters to the client's specific needs. The goal is to work as a partner with drug developers to coordinate activities throughout the testing process and provide access to data in real time as it's produced by our laboratory."

The decision to create AIT Bioscience was based on AIT's desire to improve upon the traditional CRO model. The new company will provide clients the capability to monitor sample activity from point of collection to the final report in a completely paperless environment that assures correctness from one step to the next. Instead of addressing issues after the fact, the company aims to prevent them with novel electronic systems that reject potential deviations and errors in real time.

With a newly constructed laboratory in Indianapolis, AIT Bioscience will be fully operational by the fall of 2009.

Joining Shoup at AIT Bioscience are industry veterans with numerous years of experience in bioanalytical testing.
 -- Timothy P. Grever serves as AIT Bioscience laboratory director. Grever
 comes to AIT Bioscience from Bioanalytical Systems, Inc. in West
 Lafayette, Ind., where he has held several positions over the past ten
 years, the most recent being director of bioanalytical operations
 where he led a 54-member bioanalytical team.
 -- Brian D. Beato, Ph.D. serves as senior scientist, mass spectrometry.
 Prior to joining AIT Bioscience, Beato served as laboratory and
 technical manager for Covance Bioanalytical Services in Indianapolis,
 Ind., where he helped start up and expand a bioanalytical LC/MS/MS
 laboratory. Beato possesses more than 17 years of experience in
 quantitative pharmaceutical analysis and method development, the
 majority in bioanalytical LC/MS/MS.

 -- Laurel Branstrator will assist AIT Bioscience as director of quality
 assurance GxP. She has most recently offered her expertise to the
 industry via her consulting firm, LEB Consulting Services. Prior to
 her consulting work, she served as senior director of quality
 assurance at Bioanalytical Systems, Inc.




AIT Bioscience partnered with Indianapolis branding firm Miles Design (http://www.milesdesign.com/) to develop the new brand identity including the logo, marketing materials and website. Miles Design principal Josh Miles stated, "Working with AIT's new bioscience venture is very exciting for us - especially because it's an opportunity to build on a strong relationship with an existing partner. Internally, we had always hoped to 'find another AIT.' So when it actually happened, we were thrilled."

About AIT Bioscience:

AIT Bioscience, LLC, headquartered in Indianapolis, Ind., is a bioanalytical contract research organization supporting pre-clinical, Phase I, II, and III clinical trials. AIT Bioscience's mission is to create a new standard for quantitative bioanalytical analysis and drug development in support of small biotech and large Pharma companies. Learn more about AIT Bioscience at http://www.aitbioscience.com/.
 Contact: Raquel Bahamonde
 Executive Director of Corporate Communications
 Phone: (317) 243-3894, ext. 476
 Cell: (317) 308-0064
 E-mail: rbahamonde@aitlabs.com



CONTACT: Raquel Bahamonde, Executive Director of Corporate Communications of AIT Laboratories, +1-317-243-3894, ext. 476, Cell: +1-317-308-0064, rbahamonde@aitlabs.com

Web Site: http://www.aitbioscience.com/
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 2009
Words:683
Previous Article:Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R).
Next Article:OPEN CASTING CALL IN NEW YORK CITY FOR YOUNG BOYS & GIRLS FOR UPCOMING UNIVERSAL PICTURES FEATURE FILM.


Related Articles
NEW AMERITECH ADVERTISING WILL RING IN SWEEPING TRANSFORMATION FOR CUSTOMERS
NEW AMERITECH ADVERTISING WILL RING IN SWEEPING TRANSFORMATION FOR CUSTOMERS
NeoTherapeutics' New Class of Alzheimer's Drug Begins Patient Trials in Canada
NeoTherapeutics' Files Investigational New Drug Application with FDA For Lead Compound, AIT-082
Walk-In Low Cost Allergy Screens Now Offered Through UCI Health Systems.
Allergy Immuno Technologies, Inc. Announces Third Quarter Financial Results.
AIT Laboratories Expands Pharma Services.
Professional Skin Care Company OrthoNeutrogena Becomes Ortho Dermatologics.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters